The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
6 Aug 2025 (In 3 weeks) Date | | 7.5 Cons. EPS | - EPS |
29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
19 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
6 Aug 2025 (In 3 weeks) Date | | 7.5 Cons. EPS | - EPS |
29 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
29 Apr 2025 Date | | - Cons. EPS | - EPS |
19 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Martine A. Rothblatt CEO | XFRA Exchange | US91307C1027 ISIN |
US Country | 1,305 Employees | - Last Dividend | 23 Sep 2009 Last Split | 17 Jun 1999 IPO Date |